Genzyme to Buy Ilex Oncology for $1 Billion in Stock Deal
- Share via
Biotechnology firm Genzyme Corp. said Thursday that it was buying Ilex Oncology Inc. for $1 billion in stock to bolster its business of providing drugs to treat cancer.
Genzyme, based in Cambridge, Mass., said it would pay $26 a share to stockholders of San Antonio-based Ilex.
Ilex produces Campath, used to treat leukemia, and two drugs in the late stages of seeking regulatory approval.
The deal, announced after the close of trading, would represent a 22% premium over Ilex’s closing price. The shares rose 57 cents to $21.37 on Nasdaq.They jumped $3.88 in extended trading.
Shares of Genzyme rose 5 cents to $53.28 on Nasdaq. They fell $1.94 in the extended session.
Genzyme said the acquisition would reduce its earnings in the short term but add to profits in 2006.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
